Motivation. Atherosclerosis is amongst the leading causes of death globally. However, it is challenging to study in vivo or in vitro and no detailed, openly-available computational models exist. Clinical studies hint that pharmaceutical therapy may be possible. Here we develop the first detailed, computational model of atherosclerosis and use it to develop multi-drug therapeutic hypotheses. Results. We assembled a network describing atheroma development from the literature. Maps and mathematical models were produced using the Systems Biology Graphical Notation (SBGN) and Systems Biology Markup Language (SBML), respectively. The model was constrained against clinical and laboratory data. We identified five drugs that together potentially reverse advanced atheroma formation. Availability and Implementation. The map is available in the supplementary information in SBGN-ML format. The model is available in the supplementary material and from BioModels, a repository of SBML models, containing CellDesigner markup. Contact. s.watterson@ulster.ac.uk Supplementary Information. Available from Bioinformatics online.
Introduction
Cardiovascular disease (CVD) is the primary cause of global mortality. CVD is estimated to account for 17.9m deaths worldwide each year, representing 31% of all-cause mortality worldwide (WHO, 2018) and 45% of all-cause mortality within Europe (Wilkins, 2017) . Such a prevalent condition incurs a significant financial burden, accounting for 17% of all healthcare expenditure in the USA. Age is a significant risk factor and with an aging population, the cost of CVD related therapies is predicted to almost triple in the USA from $273 billion in 2010 to $818
Methods
A list of the cell types involved in atherosclerosis was compiled from the existing literature (see supplementary table S4 ). Each article identified was also searched for references to proteins and small molecules with each entity found considered for the model. A protein or small molecule was incorporated if its biological source, presence within a compartment and influence on atherogenesis (however minor) were all described. The model was assembled with CellDesigner (Funahashi, 2008) using SBGN with mass action and Michaelis-Menten equations primarily used to describe the dynamics. The resulting model was exported to SBGN-ML file format to disseminate the visual map and to SBML file format to disseminate the mathematical model. It was subsequently analysed using MATLAB software (https://www.mathworks.com).
We considered dynamics for three lipid profiles: high risk, mediumrisk and low-risk comprising LDL concentrations of 190 mg/dl, 110 mg/dl (https://www.nhlbi.nih.gov/health/resources/heart/heartcholesterol-hbc-what-html) and 50mg/dl (O'Keefe, 2004) , respectively and HDL concentrations of 40 mg/dl, 50 mg/dl and 50 mg/dl, respectively (Boden, 2000) . Atherosclerosis is considered to be a chronic condition. Hence, we considered plaque formation across a representative time scale of 80 years. The BRENDA enzyme database was searched for relevant known rate parameters (Placzek, 2017) . In order to constrain parameters with unknown values, PubMed and Google Scholar searches were undertaken to find studies describing representative concentrations of the cells, proteins and small molecules involved. This enabled us to compile a series of clinical observations. Unknown parameters were optimized so as to maximize the agreement between the behavior of the model and these observations (see tables 1 and 2).
There are between 5 and 800 cells within a plaque area per high powered field (HPF) at 400x magnification (Brandl, 1997) , where one HPF displays approximately 0.2mm2 of plaque area (Bonanno, 2000) . We estimate that a plaque contains between 25 and 4000 cells per mm2. Average plaque area has been shown to be 15.2mm2 (von Birgelen, 1998) , giving the number of cells in a plaque as being between 380 and 60800. Using this result and the references shown, we identified the quantitative and qualitative constraints outlined in tables 1 and 2.
The model was replicated in MATLAB and simulated using the nonstiff differential equation solver function 'ode23t'. To ensure accurate replication, the SBML version of the model was also simulated using the SBML ODE Solver built into CellDesigner. Initial conditions for each entity were estimated using control group data in cardiovascular disease studies (see supplementary table S3). Concentrations of LDL and HDL in the blood were kept constant, to reflect a stable patient context.
The resulting model contains 89 ordinary differential equations (ODEs), which are detailed in supplementary table S1.
Multi-drug plaque regression therapeutic hypotheses
To demonstrate the utility of the model, we undertook to identify an optimal multi-drug intervention hypothesis that would reprogram the dynamics of the model leading to regression of advanced plaques. It has been demonstrated that multidrug approaches have the potential to exploit compound effects to yield effective interventions at lower individual and collective dosages than in comparable single-drug interventions, reducing the risk from pleotropic effects (Benson, 2017) . This is an example of the type of investigation that would be highly challenging to undertake in vivo yet can be undertaken computationally with ease.
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New models of atherosclerosis
We identified the following 9 drugs with targets in the model (targets in brackets): 2-(4-Chloro-3-(trifluoromethyl)phenoxy)-5-(((1-methyl-6-morpholino-2-oxo-1,2-dihydropyrimidin-4-yl)oxy)methyl)benzonitrile Figure 1 . A map of atherosclerotic plaque dynamics shown using the Systems Biology Graphical Notation (SBGN). (PLA2), GW4869 (SMase), Quercetin Monoglucoside (Lipoxygenase), cFMS Receptor Inhibitor III (MCSF), Bindarit (CCL2), Imatinib Mesylate (PDGF), Ustekinumab (IL12R), GSK1070806 (IL18R), SCH546738 (CXCL9, CXCL10, CXCL11, CCL5). Because PLA2, SMase and Lipoxygenase all catalyse the same interaction, we constrained these drugs to have the same concentration, giving a set of drugs with seven degrees of freedom.
We identified the optimal combination of drugs that would drive atherosclerosis regression using a genetic algorithm and a bespoke scoring function (see supplementary section S1) in MATLAB. A genetic algorithm was chosen for its ease of parallelisation and the transparency of its convergence. The analysis was run on an Intel(R) Xeon(R) CPU E5-2630 v3 @ 2.6GHz (Octo-core) CPU with 64GB of RAM running CentOS 7.
Results
A map of the model obtained is shown in Figure 1 using the SBGN schema. The model covers the liver, intestine, lumen, endothelium and tunica intima, including LDL retention, LDL oxidation, monocyte recruitment, monocyte differentiation, smooth muscle cell proliferation, phagocytosis, reverse cholesterol transport and T-cell proliferation. The cell types involved include monocytes, endothelial cells, T-cells, macrophages, foam cells, B-cells, smooth muscle cells, neutrophils, dendritic cells and mast cells. Each interaction represents a parameterized equation (see supplementary tables S1 and S2), enabling us to simulate the changing concentrations/abundances of the model as the plaque forms.
The initial conditions identified are described in supplementary table S3 and unknown parameters were optimized so that the model simultaneously satisfied the constraints described in tables 1 and 2. Along with figures S2, S3 and S4, tables 1 and 2 demonstrate consistency with the underlying unperturbed biology. Key markers for plaque development include smooth muscle cell, macrophage and foam cell and Th1 cell proliferation. Their behavior for the three risk profiles is shown in Figure 2.
Reusability of the model
The files can be opened, edited and analyzed in software supporting the SBGN-ML and SBML standards. SBML compliant software includes Copasi (Bergmann, 2017) , Cytoscape with the cy3SBML plugin (König, 2012) and Dizzy (Ramsey, 2005) . Supplementary Fig S1 shows the graphical map opened in three representative SBGN compliant editors: Newt (http://web.newteditor.org/), PathVisio (Kutmon, 2015) and VANTED with SBGN-ED extension (Czauderna, 2010) along with a subsection of the plain text, XML file.
Therapeutic hypothesis generation
We determined the following drug combination that optimally drove plaque regression. Concentrations are described as multiples of the corresponding inhibition constants, ki. 2-(4-Chloro-3-(trifluoromethyl)phenoxy)-5-(((1-methyl-6-morpholino-2-oxo-1,2-dihydropyrimidin-4-yl)oxy)methyl)benzonitrile (PLA2 and 3D show the predicted dynamics of atherosclerosis after this intervention is applied at forty years following forty years of the high risk lipid profile. We can see that smooth muscle cells, macrophages and foam cells and Th1-cell counts are all rapidly driven down by the intervention.
Discussion
CVD is a large burden on healthcare worldwide. Front line therapies for the primary and secondary prevention of atherosclerotic disease include smoking cessation, lipid management, blood pressure control, optimal control of diabetes and the use of antiplatelet agents. However, the (Henderson, 2016) . Atherosclerotic plaques are highly challenging to study due to their location. In vivo study presents logistical and ethical challenges and there are few in vitro resources. Whilst they are not a replacement for in vivo studies, computational studies have the potential to contribute nonin vivo resources that can improve our understanding of CVD.
Here we have produced the first detailed, predictive model of atherosclerosis pathophysiology and it can serve as a resource for the research community to be reused, refined and expanded in future. Models of this type can be used to predict the on-target and off-target consequences of interventions. This can be exploited in single drug development to identify the drug targets that have the greatest potential therapeutic value or in multi-drug intervention development to identify drug combinations and target combinations with the greatest potential therapeutic value (Benson, 2017) . The scale of the global CVD burden means that there is a pressing need to develop new pharmaceutical therapeutics that both address clinical need and can sustain the pharmaceutical industry as intellectual property protection expires around current therapeutics. Multi-drug interventions of the type identified here have a vast untapped potential to contribute to future therapeutics in this way.
The development of therapeutic hypotheses can form part of programmes of personalized or stratified medicine by adapting the parameters to individuals or to patient subgroups. Such parameterizations could be identified by optimizing the model to time course data or by determining the impact of single nucleotide polymorphisms on protein function.
The dynamics of the model show broad agreement with observed clinical results (see tables 1 and 2). Because the model describes spatial effects and cellular function very simply, it is unlikely to be able to recreate all clinical results exactly. Doing so would require greater complexity across length scales. However, we demonstrate order of magnitude agreement in almost all cases and show the correct qualitative dose responses. Optimizing the parameters so as to ensure a sufficiently large response to changes in lipoprotein profile for particular model components was challenging. Consequently, particular components are systematically over-estimated for the low LDL profile and the difference between high and low LDL profiles, although large, is not as great as that observed clinically. In changing the lipid profile, we adjusted the concentrations of LDL and HDL in the model. This logically does not impact upon components upstream of LDL and HDL. Hence, we would expect to see no resulting change in chylomicron or triglyceride concentrations as described in rows 28 and 29 of table 1. To see changes in chylomicron or triglyceride concentrations would require either modifying VLDL and IDL values across risk profiles or incorporating further feedback into the model.
Atherosclerosis is known to have comorbidities such as rheumatoid arthritis and depression (Gibson, 2017) . By using incorporating 'omic data from studies of other diseases, this model can be used to explore their impact on atherosclerosis as a comorbidity. Similarly, it can be used to explore the impact of therapies for other diseases on atherosclerosis either where there are targets in atherosclerosis associated pathways or through changes to 'omic profiles.
The therapeutic hypotheses identified here could be validated and developed further by experimentation in animal models (Getz, 2012) . Each animal model has limitations and none are a perfect surrogate for human atheroma. As a result, the computational model presented here would need to be adapted for each animal system and new therapeutic hypotheses would need to be generated. However, this would be the next step towards therapy development. ng/μg in plaques and 1.9 ng/μg in normal intimal tissue (Nishi, 2002) . Plaque concentration of ApoB ranges from 1.97 μg/mg to 0.13 μg/mg (Hoff, 1978) (Gupta, 1997) Decreasing the rate parameter for IFNG production by 50% reduces Tcell abundance. (Ferns, 1991) Increasing the rate parameter for PGDF production by 200% increases smooth muscle cell recruitment.
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